Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.45  

 
 

ELEVENTH AMENDMENT AND CONSENT TO SECOND AMENDED AND
  RESTATED CREDIT AGREEMENT    
    

        THIS ELEVENTH AMENDMENT AND CONSENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT, dated as of February 24, 2005 (this
"Amendment"), to the Second Amended and Restated Credit Agreement, dated as of September 30, 2003 (as amended, supplemented or otherwise modified
from time to time, the "Credit Agreement"), by and among General Electric Capital Corporation, as Agent
("Agent"), Inverness Medical Innovations, Inc. ("Innovations"), Wampole Laboratories, Inc.
and Inverness Medical (UK) Holdings Limited, as borrowers ("Borrowers"), the other Credit Parties signatory thereto, Merrill Lynch Capital, a division
of Merrill Lynch Business Financial Services Inc., as documentation agent and co-syndication agent, UBS Securities LLC, as co-syndication agent, and the lenders
signatory thereto from time to time (collectively, the "Lenders"). 

W I T N E S S E T H  

        WHEREAS, Borrowers have previously notified Agent and Lenders that Innovations intends to enter into an exploitation, research and development arrangement with
ITI Scotland Limited ("ITI"), a Scottish entity indirectly funded by the Scottish government, whereby ITI will provide significant funding and
Innovations, through Stirling Medical Innovations Limited, its wholly-owned Scottish subsidiary ("Scottish Newco"), will commit to develop and
commercialize intellectual property (the "Development Arrangement"); 

        WHEREAS,
in connection with the Development Arrangement, Innovations and Scottish Newco will enter into (a) a Research and Development Agreement with ITI, and (b) an
Exploitation Agreement with ITI, in the forms attached hereto as Exhibit A (collectively, the "Scottish
Agreements"); 

        WHEREAS,
Agent and Requisite Lenders previously consented to the formation of Scottish Newco; 

        WHEREAS,
Borrowers are requesting Agent and Requisite Lenders consent to the commencement of operations by Scottish Newco in accordance with the terms of the Scottish Agreements through
the execution and delivery of the Scottish Agreements by Scottish Newco and performance of its obligations thereunder; and 

        WHEREAS,
Agent and Requisite Lenders have agreed to amend the Credit Agreement in the manner, and on the terms and conditions, provided for herein. 

        NOW
THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the
parties hereto agree as follows: 

        1.    Definitions.    Capitalized terms not otherwise defined herein (including in the Recitals) shall have the
meanings ascribed to them in the Credit Agreement. 

        2.    Scottish Newco.    Notwithstanding anything to the contrary contained in the Tenth Amendment and Consent to
Second Amended and Restated Credit Agreement, dated as of January 31, 2005, as of the Effective Date (as hereinafter defined), Agent and Requisite Lenders hereby (A) agree that the
Credit Parties shall be permitted to loan, transfer and otherwise make available to Scottish Newco funds and/or assets to the extent contemplated by the Scottish Agreements;  provided such loan or
transfer would be permitted under the Credit Agreement if Scottish Newco were a Credit Party thereunder and (B) Scottish
Newco shall be permitted to own assets and conduct business to the extent contemplated by the Scottish Agreements; providedsuch actions would be
permitted by the Credit Agreement if Scottish Newco were a Credit Party thereunder; provided further that the consents and agreements of Agent and
Requisite Lenders set forth above are expressly conditioned on the satisfaction of all of the following conditions in Agent's reasonable discretion, and the Borrowers and 

 

the
other Credit Parties hereby covenant and agree, within sixty (60) days following the date hereof or such other period as may be specified below, as follows: 

        (a)    Joinder.    Borrowers shall deliver a joinder agreement, in form and substance satisfactory to Agent, duly
executed by Scottish Newco pursuant to which, inter alia, Scottish Newco joins the Credit Agreement and the other Loan Documents as a European Credit
Party. 

        (b)    Guaranty.    Borrowers shall deliver a guaranty, in form and substance satisfactory to Agent, duly executed by
Scottish Newco, pursuant to which Scottish Newco agrees to guaranty the Obligations of the European Credit Parties under the Loan Documents. 

        (c)    Security Interest and Code Filings.    

          (i)  Scottish
Newco shall have granted a valid first priority perfected security interest (subject to Permitted Encumbrances) in all of its assets to secure the Obligations
of the European Credit Parties and shall have executed all documents (including financing statements under the Code (or foreign equivalent) and other applicable documents under the laws of any
jurisdiction with respect to the perfection of Liens in form and substance reasonably acceptable to Agent) as Agent may request in order to perfect its security interest in such assets. 

         (ii)  Scottish
Newco shall provide copies of Code (or the foreign equivalent thereof) search reports listing all effective financing statements (or equivalent information)
that name Scottish Newco as debtor, together with copies of such financing statements (or equivalent information), none of which shall cover the assets of Scottish Newco. 

        (iii)  Within
ninety (90) days of the date hereof or such longer period as Agent shall consent to in its sole discretion, Scottish Newco shall provide Control Letters
from (A) all issuers of uncertificated securities and financial assets held by Scottish Newco, (B) all securities intermediaries with respect to all securities accounts and securities
entitlements of Scottish Newco, and (C) all futures commission agents and clearing houses with respect to all commodities contracts and commodities accounts held by Scottish Newco. 

        (d)    Waivers.    To the extent requested by Agent in its sole discretion, within ninety (90) days of the date
of such request or such longer period as Agent shall consent to in its sole discretion, Agent, on behalf of Lenders, shall have received landlord waivers and consents, bailee letters and mortgagee
agreements in form and substance reasonably satisfactory to Agent, in respect of Scottish Newco. 

        (e)    Pledge Amendment.    Agent shall have received a pledge amendment to that certain Pledge Agreement, dated as of
November 14, 2002, by and among Swissco and Agent (as amended, the "Swiss Pledge Agreement"), in form and substance satisfactory to Agent, duly
executed by an authorized officer of Swissco, pursuant to which Swissco pledges one hundred percent (100%) of the issued and outstanding Stock of Scottish Newco (the "Scottish
Newco Stock") to Agent, together with all collateral and ancillary documentation required by the Swiss Pledge Agreement, including, without limitation, original certificates
representing the Scottish Newco Stock pledged by Swissco. 

        (f)    Cash Management.    Within ninety (90) days of the date hereof or such longer period as Agent shall
consent to in its sole discretion, Agent shall have received tri-party blocked account agreements, in form and substance reasonably satisfactory to Agent, duly executed and delivered by
Scottish Newco and each bank where Scottish Newco has established a deposit or disbursement account (other than payroll accounts), in accordance with the requirements set forth in  Section 1.8 and
Annex C of the Credit Agreement. 

2

 

        (g)    Schedules.    Agent shall have received updated Schedules to the Credit Agreement and such other Loan Documents
as may be required in connection with the joinder of Scottish Newco, to reflect the joinder of Scottish Newco to such agreements, in form and substance satisfactory to Agent. 

        (h)    Organizational Documents and Good Standing.    Agent shall have received a copy of Scottish Newco's
(i) organizational documents and all amendments thereto and (ii) good standing certificates or the foreign equivalent and certificates of qualification to conduct business in each
jurisdiction where its ownership or lease of property or the conduct of its business requires such qualification, each dated a recent date and certified by the applicable authorized Governmental
Authority. 

        (i)    Bylaws and Resolutions.    Agent shall have received a copy of (i) Scottish Newco's bylaws (or foreign
equivalent thereof) and all amendments thereto, and (ii) resolutions of Scottish Newco's board of directors and, to the extent required under applicable law, stockholders, approving and
authorizing the execution, delivery and performance of the Loan Documents to which Scottish Newco is, or will be a party and the transactions to be consummated in connection therewith, each certified
by an authorized officer of Scottish Newco as being in full force and effect without any modification or amendment as of the Effective Date. 

        (j)    Incumbency.    Agent shall have received a signature and incumbency certificate of the officers of Scottish
Newco, certified by an officer of Scottish Newco as being true, accurate, correct and complete in all respects. 

        (k)    Scottish Agreements.    On or before the loan or transfer of any funds to Scottish Newco of the commencement by
Scottish Newco of any activities, Agent shall have received executed copies of the Scottish Agreements, together with all amendments thereto, and all documentation delivered in connection therewith
(all of which shall be in form and substance reasonably satisfactory to Agent), certified by an authorized officer of Scottish Newco to be true and complete and in full force and effect as of the
Effective Date. 

        (l)    Opinion of Counsel.    Agent shall have received legal opinions of counsel acceptable to Agent, which shall
provide (subject to customary qualifications) that (i) the Loan Documents have been duly authorized, executed and delivered by, and are enforceable against Scottish Newco, and (ii) such
other opinions as Agent may reasonably request, all in form and substance satisfactory to Agent. 

        (m)    Appointment of Agent for Service of Process.    Agent shall have received evidence that the Connecticut office
of CT Corporation has been appointed as agent for service of process for Scottish Newco. 

        The
Borrowers and each of the other Credit Parties hereby acknowledge and agree that the failure to satisfy any of the deliveries or conditions set forth above in this  Section 2 on or prior to the date
required as set forth above in connection with each such delivery or condition, as applicable, shall constitute
an immediate Event of Default under the Credit Agreement. At such time as the conditions set forth in (a) through (m) above shall have been satisfied, Scottish Newco shall constitute a
European Credit Party and shall not be subject to any restrictions other than those applicable to European Credit Parties or Credit Parties and set forth in the Credit Agreement or in the other Loan
Documents. 

        3.    Amendments to Credit Agreement.    Immediately following satisfaction of each of the conditions set forth in  Section 2
hereof, Annex A to the Credit Agreement shall be amended by deleting the definition of
"Excluded European Subsidiary" and replacing it with the following: 

"Excluded European Subsidiary" means (a) Unipath BV, an entity organized under the laws of The Netherlands; (b) Unipath Management
Limited, a company organized under the laws of England 

3

 

and
Wales; (c) Unipath Scandinavia AB, an entity organized under the laws of Sweden; (d) Inverness Medical Benelux Bvab, an entity organized under the laws of Belgium;
(e) Orgenics and each of the subsidiaries of Orgenics; (f) Inverness Medical Australia Pty Ltd.; and (g) Inverness Medical (Shanghai) Co., Ltd." 

        4.    Representations and Warranties.    To induce Agent and Lenders to enter into this Amendment, the Credit Parties
hereby, jointly and severally, represent and warrant that: 

        (a)   The
execution, delivery and performance by each Credit Party of this Amendment and the performance of the Credit Agreement as amended by this Amendment (the
"Amended Credit Agreement"): (i) are within such Person's corporate, company or partnership power; (ii) have been (or will be prior to
execution thereof) duly authorized by all necessary corporate, limited liability company or limited partnership action; (iii) do not contravene any provision of such Person's charter, bylaws or
equivalent constitutive documents or partnership or operating agreement, as applicable; (iv) do not violate any law or regulation, or any order or decree of any court or Governmental Authority;
(v) do
not conflict with or result in the breach or termination of, constitute a default under or accelerate or permit the acceleration of any performance required by, any indenture, mortgage, deed of trust,
lease, agreement or other instrument to which such Person is a party or by which such Person or any of its property is bound; (vi) do not result in the creation or imposition of any Lien upon
any of the property of such Person, other than a Lien in favor of Agent; and (vii) do not require the consent or approval of any Governmental Authority or any other Person except those which
will have been duly obtained, made or complied with prior to the Effective Date. 

        (b)   This
Amendment has been duly executed and delivered by or on behalf of each of the Credit Parties. 

        (c)   This
Amendment constitutes a legal, valid and binding obligation of each of the Credit Parties, enforceable against each of them in accordance with its terms. 

        (d)   No
Default or Event of Default has occurred and is continuing or would result after giving effect to the provisions of this Amendment. 

        (e)   No
action, claim or proceeding is now pending or, to the knowledge of any Credit Party, threatened against such Credit Party, at law, in equity or otherwise, before any
court, board, commission, agency or instrumentality of any foreign, federal, state, or local government or of any agency or subdivision thereof, or before any arbitrator or panel of arbitrators, which
(i) challenges any Credit Party's right or power to enter into or perform any of its obligations under this Amendment or any other Loan Document to which it is or will be, a party, or the
validity or enforceability of this Amendment, the Credit Agreement or any Loan Document or any action taken thereunder, or (ii) has a reasonable risk of being determined adversely to any Credit
Party and that, if so determined, could reasonably be expected to have a Material Adverse Effect after giving effect to this Amendment. 

        (f)    The
representations and warranties of the Credit Parties contained in the Amended Credit Agreement and each other Loan Document shall, after giving effect hereto) be
true and correct on and as of (i) the date hereof, and (ii) the Effective Date, in each case, with the same effect as if such representations and warranties had been made on and as of
such date, except that any such representation or warranty which is expressly made only as of a specified date need be true only as of such date. 

        5.    No Other Amendments/Waivers.    Except as expressly provided herein (a) the Credit Agreement and the
other Loan Documents shall be unmodified and shall continue to be in full force and effect in accordance with their terms, (b) the consents and agreements of the Agent and Requisite Lenders set
forth herein shall be limited strictly as written and shall not constitute a consent or agreement to any 

4

 

transaction
not specifically described in connection with any such consent and/or agreement, and (c) this Amendment shall not be deemed a waiver of any term or condition of any Loan Document
and shall not be deemed to prejudice any right or rights which Agent or any Lender may now have or may have in the future under or in connection with any Loan Document or any of the instruments or
agreements referred to therein, as the same may be amended from time to time. 

        6.    Affirmation of Obligations.    Each of the Credit Parties hereby acknowledges, agrees and affirms (a) its
obligations under the Credit Agreement and the other Loan Documents, including, without limitation, its guaranty obligations thereunder, (b) that such guaranty shall apply to the Obligations in
accordance with the terms thereof, (c) the grant of the security interest in all of its assets pursuant to the Loan Documents and (d) that such liens and security interests created and
granted are valid and continuing and secure the Obligations in accordance with the terms thereof. 

        7.    Outstanding Indebtedness; Waiver of Claims.    Each of Borrowers and the other Credit Parties hereby
acknowledges and agrees that as of February 24, 2005 (a) the outstanding balance of the European Revolving Loan is $11,000,000 and (b) the outstanding balance of the US Revolving
Loan is $20,000,000. Borrowers and each other Credit Party hereby waives, releases, remises and forever discharges Agent, Lenders and each other Indemnified Person from any and all claims, suits,
actions, investigations, proceedings or demands arising out of or in connection with the Credit Agreement (collectively, "Claims"), whether based in
contract, tort, implied or express warranty, strict liability, criminal or civil statute or common law of any kind or character, known or unknown, which any Borrower or any other Credit Party ever
had, now has or might hereafter have against Agent or Lenders which relates, directly or indirectly, to any acts or omissions of Agent, Lenders or any other Indemnified Person on or prior to the
Effective Date, provided, that no Borrower nor any other Credit Party waives any Claim solely to the extent such Claim relates to Agent's or any
Lender's gross negligence or willful misconduct. 

        8.    Expenses.    Borrowers hereby reconfirm their obligations pursuant to  Section 11.3 of the Credit Agreement to pay and
reimburse Agent for all reasonable costs and expenses (including, without limitation, reasonable
fees of counsel) incurred in connection with the negotiation, preparation, execution and delivery of this Amendment and all other documents and instruments delivered in connection herewith. 

        9.    Effectiveness.    Upon satisfaction in full in the judgment of Agent of each of the following conditions, this
Amendment shall be deemed effective as of February 24, 2005 (the "Effective Date"): 

        (a)    Amendment.    Agent shall have received four (4) original signature pages to this Amendment, duly
executed and delivered by Agent, Lenders, and each of the Credit Parties. 

        (b)    Payment of Fees and Expenses.    Borrowers shall have paid to Agent all costs, fees and expenses owing in
connection with this Amendment and the other Loan Documents and due to Agent (including, without limitation, reasonable legal fees and expenses). 

        (c)    Representations and Warranties.    The representations and warranties of or on behalf of each of the Credit
Parties in this Amendment shall be true and correct on and as of the date hereof and the Effective Date. 

        10.    GOVERNING LAW.    THIS AMENDMENT SHALL BE GOVERNED BY, AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE
OF NEW YORK. 

        11.    Counterparts.    This Amendment may be executed by the parties hereto on any number of separate counterparts
and all of said counterparts taken together shall be deemed to constitute one and the same instrument. 

5

 

        IN
WITNESS WHEREOF, this Amendment has been duly executed as of the date first written above. 

	 
	 	 
	 	 

	

 	
 	
BORROWERS
	

 	
 	

WAMPOLE LABORATORIES, LLC.

INVERNESS MEDICAL (UK) HOLDINGS LIMITED
	

 	
 	

By:	
 	

/s/  ANTHONY J. BERNARDO      

	 	 	Name: Anthony J. Bernardo

Title: Duly Authorized Signatory

6

 

	 	 	AGENT AND LENDERS
	

 	
 	

GENERAL ELECTRIC CAPITAL

CORPORATION, as Agent and Lender
	

 	
 	

By:	
 	

/s/  KEITH KENNEDY      
 Duly Authorized Signatory
	

 	
 	

MERRILL LYNCH CAPITAL, a division of

Merrill Lynch Business Financial Services Inc.,

as a Lender
	

 	
 	

By:	
 	

/s/  LUIS VIERA      
 Duly Authorized Signatory
	

 	
 	

UBS AG, CAYMAN ISLANDS BRANCH,

as a Lender
	

 	
 	

By:	
 	

/s/  EDWARD CRIPPS      
 Duly Authorized Signatory
	

 	
 	

By:	
 	

/s/  JOSELIN FERNANDES      
 Duly Authorized Signatory

7

 

        The
following Persons are signatories to this Amendment in their capacity as Credit Parties and not as Borrowers. 

	 
	 	 
	 	 

	

 	
 	

INVERNESS MEDICAL INNOVATIONS, INC.

INVERNESS MEDICAL, INC.

UNIPATH ONLINE, INC.

OSTEX INTERNATIONAL, INC.

INVERNESS MEDICAL INTERNATIONAL HOLDING CORP.

INVERNESS MEDICAL INTERNATIONAL HOLDING CORP. II

UNIPATH LIMITED

APPLIED BIOTECH, INC.

FOREFRONT DIAGNOSTICS, INC.

MORPHEUS ACQUISITION CORP.

INVERNESS MEDICAL INVESTMENTS, LLC

INVERNESS MEDICAL CANADA INC.

INNOVATIONS RESEARCH LLC

ADVANTAGE DIAGNOSTICS CORPORATION IVC INDUSTRIES, INC.
	

 	
 	

By:	
 	

/s/  ANTHONY J. BERNARDO      

	 	 	Name: Anthony J. Bernardo

Title: Duly Authorized Signatory
	

 	
 	

ORGENICS INTERNATIONAL HOLDINGS BV

INVERNESS MEDICAL SWITZERLAND GMBH

INVERNESS MEDICAL GERMANY GMBH

UNIPATH DIAGNOSTICS GMBH

CAMBRIDGE DIAGNOSTICS IRELAND LIMITED

PREGYMED GMBH

SCANDINAVIAN MICRO BIODEVICES APS

SELFCARE TECHNOLOGY, INC.

VIVA DIAGNOSTIKA—DIAGNOSTISCHE PRODUKTE—GMBH

DMD, DIENSTLEISTUNGEN & VERTRIEB FUR MEDIZIN UND DIAGNOSTIK GMBH

INVERNESS MEDICAL EURASIA LIMITED

INVERNESS MEDICAL FRANCE S.A.S.
	

 	
 	

By:	
 	

/s/  PAUL T. HEMPEL      

	 	 	Name: Paul T. Hempel

Title: Duly Authorized Signatory

8

QuickLinks

ELEVENTH AMENDMENT AND CONSENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENTSummary of Named Executive Officer Compensation

Exhibit 10.11

Coventry Health Care,
Inc. (the “Company”)
Summary of Named
Executive Officer Compensation 

Base Salary 

The following table sets forth the
current base salaries provided to the Company’s Chief Executive Officer and four most
highly compensated executive officers: 

	Executive Officer	Current Salary
	Allen F. Wise (former Chief Executive Officer and President)	$  750,000 
	Dale B. Wolf, Chief Executive Officer	$  850,000 
	Thomas P. McDonough, President	$  850,000 
	Harvey C. DeMovick, Jr	$  600,000 
	Bernard J. Mansheim, M.D	$  410,000 

Executive Management
Incentive Plan 

2004 Criteria and Bonuses 

The Company’s Chief Executive
Officer and four most highly compensated officers are also eligible to receive a bonus
each year under the Company’s 2004 Executive Management Incentive Plan (the “2004 EMIP”),
which was previously filed as Exhibit 10.20 to the Company’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2003. For fiscal year 2004, bonuses under the 2004 EMIP were
based on the attainment
of budgeted EPS (earnings per share). The bonuses paid to the Company’s Chief
Executive Officer and four most highly compensated executive officers for performance in
fiscal year 2004 is set forth below: 

	Executive Officer	Bonus for 2004
	Allen F. Wise (former Chief Executive Officer and President)	$ 2,000,000 1 
	Dale B. Wolf, Chief Executive Officer	$    750,000 2 
	Thomas P. McDonough, President	$ 1,250,000    
	Harvey C. DeMovick, Jr	$    400,000 3 
	Bernard J. Mansheim, M.D	$    350,000    

2005 Criteria 

Pursuant to the Company’s 2005
Executive Management Incentive Plan (the “2005 EMIP”), which was previously
filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K, dated November 23,
2004, the Compensation Committee of the Company’s Board of Directors approved the
bonus criteria for fiscal year 2005 under the 2005 EMIP. For fiscal year 2005, bonuses
under the 2005 EMIP will be based on the attainment of budgeted EPS. 

1 Plus $600,000 deferred under the 2004 Mid-Term Executive Retention Program.

2 Plus $500,000 deferred under the 2004 Mid-Term Executive Retention Program.

3 Plus $100,000 deferred under the 2004 Mid-Term Executive Retention Program.

2004 Mid-Term Executive
Retention Program 

In addition to their base salaries
and bonuses, the Company’s Chief Executive Officer and four most highly compensated
executive officers are also eligible to receive an annual cash and stock credit allocation
to an account under the 2004 Mid-Term Executive Retention Program, effective July 1, 2004,
a copy of which is filed herewith as Exhibit 10.26 to this Annual Report on Form 10-K for
the fiscal year ended December 31, 2004. The amount of the allocation is a percentage of
base salary and bonus earned for the prior year and ranges from 0% to 55%, based on
performance. Each account will fully vest on July 1, 2006 and will be paid out in cash,
subject to the attainment of pre-established performance criteria for each performance
period. In the event the performance criteria is not met in any period, the award for that
period is forfeited. For the nine-month period ended December 31, 2004, the performance
criteria was based on the attainment of budgeted EPS. The performance criteria for the
nine months ended December 31, 2004 was met, and the participants were credited the
following amounts in accounts under the 2004 Mid-Term Executive Retention Program: 

	Executive Officer	2004 Allocation	 2004 Stock 
Credit Allocation
	Allen F. Wise (former Chief Executive Officer 
and President	$ 1,677,500 	$ 838,750 
	Dale B. Wolf, Chief Executive Officer	$    680,000 	$ 340,000 
	Thomas P. McDonough, President	$    680,000 	$ 340,000 
	Harvey C. DeMovick, Jr	$    255,000 	$ 127,500 
	Bernard J. Mansheim, M.D	$    193,750 	$   96,875 

Other Benefit Plans and
Arrangements 

In addition to their base salaries
and bonuses, the Company’s Chief Executive Officer and four most highly compensated
executive officers are also eligible to: 

	o	  	
Participate in the Company’s long-term incentive plan under its 2004 Incentive Plan,
a copy of which is filed herewith as Exhibit 10.22 to this Annual Report on Form 10-K for
the fiscal year ended December 31, 2004, which can be in the form of stock options,
restricted stock or cash; and 

	o	  	
Participate in the Company’s Supplemental Executive Retirement Plan, a copy of which
is filed herewith as Exhibit 10.36 to this Annual Report on Form 10-K for the fiscal year
ended December 31, 2004.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}]]